Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › omadacycline

omadacycline

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials of omadacycline

6 trials tracked of omadacycline: 4 in phase 3 or 4 and 3 with published results. The most-cited published study has 229 citations.

6Trials tracked
4Phase 3 & 4
0Recruiting
3With published results
Phase distribution
Phase 3 4 Phase 2 1 Phase 1 1
  1. Phase 3 Omadacycline vs Moxifloxacin for the Treatment of CABP (EudraCT #2013-004071-13) Completed · 229 cited
  2. Phase 3 Oral Omadacycline vs. Oral Linezolid for the Treatment of ABSSSI Completed · 94 cited
  3. Phase 3 Omadacycline Versus Linezolid for the Treatment of ABSSSI (EudraCT #2013-003644-23) Completed · 46 cited
  4. Phase 3 Omadacycline vs. Moxifloxacin for the Treatment of Community-Acquired Bacterial Pneumonia Completed
  5. Phase 2 IV or IV/PO Omadacycline vs. IV/PO Levofloxacin for the Treatment of Acute Pyelonephritis Completed
  6. Phase 1 Study to Evaluate the PK of PO Omadacycline in Adults With Community-Acquired Bacterial Pneumonia Completed

Showing the 6 most-cited and recently-updated of 6 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
FDA approves nuzyra for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections in adults
Infectious Disease FDA Approval
FDA approves nuzyra for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections in adults FDA approves nuzyra for treating bacterial infections in adult patients safely
The FDA granted approval for nuzyra to treat community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections i…
The FDA has approved nuzyra to treat community-acquired bacterial pneumonia and skin infections in adults. This regulatory decision confirms…
FDA May 19, 2026